NetraMark Holdings (AIAI) Q2 2026 earnings summary

Executive summary

• Achieved key milestones in oncology, neuroscience, commercial expansion, and capital markets during the second quarter ended March 31, 2026.

• Advanced NetraAl platform integration for clinical trial enrichment and patient stratification, with applications in oncology, Alzheimer's, depression, and psychedelic medicine.

• Strengthened commercial pipeline and proposal activity, with ongoing integration into Worldwide Clinical Trials' proposal process.

Financial highlights

• Closed a Cdn $3.5 million private placement, bolstering the balance sheet for commercial and scientific initiatives.

• Fiscal year to date, signed customer agreements totaling approximately Cdn $3.09 million in contract value.

• Recognized approximately Cdn $129,000 as revenue in the first half of fiscal 2026, with Cdn $2.96 million in contracted backlog.

Outlook and guidance

• Revenue from backlog expected to be recognized as services are delivered, including post-clinical trial data readouts.

• Management anticipates continued commercial growth and further integration of NetraAl into clinical trial planning.

• Forward-looking statements highlight expectations for technology adoption, revenue recognition, and benefits from TSX listing, subject to risks and uncertainties.